TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02405091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854
Study: NCT03870139

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cerebral stimulation
Description: Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various health conditions. However, its ergogenic effect still has controversial results.
Study: NCT03742791

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched Placebo oral solution
Study: NCT03229200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Subjects will continue with the current ibrutinib dosing regimen established in the parent ibrutinib study.
Study: NCT03870139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebral stimulation
Description: Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various health conditions. However, its ergogenic effect still has controversial results.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebral stimulation
Description: Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various health conditions. However, its ergogenic effect still has controversial results.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral stimulation
Description: Peripheral electrical stimulation (PES) activates a complex neural network involving a series of neurotransmitters and receptors capable of promoting segmental and extrasegmental analgesia. Moreover, recent evidence has shown that PES can activate brain motor areas such as primary motor cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral stimulation
Description: Peripheral electrical stimulation (PES) activates a complex neural network involving a series of neurotransmitters and receptors capable of promoting segmental and extrasegmental analgesia. Moreover, recent evidence has shown that PES can activate brain motor areas such as primary motor cortex.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral stimulation
Description: Peripheral electrical stimulation (PES) activates a complex neural network involving a series of neurotransmitters and receptors capable of promoting segmental and extrasegmental analgesia. Moreover, recent evidence has shown that PES can activate brain motor areas such as primary motor cortex.
Study: NCT03230266

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Collection of intra-peritoneal catheters for insulin infusion
Description: Collection of intra-peritoneal catheters for insulin infusion
Study: NCT02461576

Intervention type: DEVICE
Intervention: Xpert HIV-1 VL Assay
Description: in vitro diagnostic test to quantify HIV-1 RNA
Study: NCT01844414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parolee Comprehensive Care + Phone Coach
Description: A nurse case managed and specialized hepatitis education program with the hepatitis A/B (HAV/HBV) vaccination series (to all eligible) and coach-facilitated mentoring (mostly by cell-phone).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parolee Brief HBV Program + Phone Coach
Description: A brief hepatitis/HIV education program with the Hepatitis A/B vaccine series and coach-facilitated mentoring.
Study: NCT03474198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: 10mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: 5mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: 5mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: 5mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: 5mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: 5mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide
Description: 25mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: 25mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: 25mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: 25mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: 25mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: 15mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: 15mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: 15mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: 15mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: 600mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: 600mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: 600mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine
Description: 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine
Description: 1200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: 1000mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: 400mg once daily for 2 weeks then 200mg 3x a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: 35mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: 35mg/kg
Study: NCT01723540

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minilaparotomy vs laparoscopy
Description: MC-group will undergo ultrasonic dissection assisted minilaparotomy cholecystectomy ans patients in the LC-grout will undergo laparoscopic cholecystectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minilaparotomy vs laparoscopy
Description: MC-group will undergo ultrasonic dissection assisted minilaparotomy cholecystectomy ans patients in the LC-grout will undergo laparoscopic cholecystectomy
Study: NCT04025177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin Injection
Description: The dose of indomethacin will be 0.1 mg/kg/dose, based on birth weight, intravenously every 24 hours for a total of 3 doses. Doses 2 and 3 may be administered between 23.5 and 24.5 hours after the previous dose. Doses will be rounded to two significant figures.
Study: NCT01302054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg
Description: Fesoterodine sustained release tablets once every morning at 4 mg dose for first week, followed by 11 weeks at 8 mg strength.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for fesoterodine 4 and 8 mg for a total of 12 weeks.
Study: NCT01945684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Maximum dose 360 U

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Maximum dose 360 U
Study: NCT00847015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib will be administered at a dose of 25mg orally once daily for 2 consecutive weeks followed by a 1 week rest period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1,000 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin 35 mg/m\^2 will be administered intravenously on days 1 and 8.
Study: NCT02419170

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of care surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized mature dendritic cell vaccine
Study: NCT03153488

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI
Description: All participants will perform one MRI session before initiation of treatment. The imaging session will last about an hour including the structural and functional MRI portions. The subjects lie on a padded scanner couch in a dimly illuminated room, and wear foam earplugs to attenuate scanner sounds.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI
Description: All participants will perform one MRI session before initiation of treatment. The imaging session will last about an hour including the structural and functional MRI portions. The subjects lie on a padded scanner couch in a dimly illuminated room, and wear foam earplugs to attenuate scanner sounds.
Study: NCT01943552

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipratropium bromide
Description: ipratropium bromide
Study: NCT02473276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: preservative free morphine given either via an epidural or intrathecal catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: preservative free morphine given either via an epidural or intrathecal catheter
Study: NCT01844414

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Group
Description: Control Group: A brief general health information program with one-on-one coaching and the Hepatitis A/B vaccine
Study: NCT03347461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otiprio
Description: Otiprio is a single-dose, physician-administered, sustained-exposure otic fluoroquinolone antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement surgery. Otoprio (6% ciprofloxacin, 60 mg/mL) will be administered through the tube lumen by the otolaryngologist immediately after tympanostomy surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprodex
Description: Ciprodex is a combined antibiotic and steroid ear drop used to treat otitis media with tympanostomy tubes. Four drops of Ciprodex (0.14mL) instilled by the otolaryngologist into the affected ear immediately after tympanostomy surgery. Each mL of Ciprodex contains ciprofloxacin hydrochloride 0.3 % (equivalent to 3 mg ciprofloxacin base) and dexamethasone 0.1 % equivalent to 1 mg dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprodex
Description: Ciprodex is a combined antibiotic and steroid ear drop used to treat otitis media with tympanostomy tubes. Four drops of Ciprodex (0.14mL) instilled by the otolaryngologist into the affected ear immediately after tympanostomy surgery. Each mL of Ciprodex contains ciprofloxacin hydrochloride 0.3 % (equivalent to 3 mg ciprofloxacin base) and dexamethasone 0.1 % equivalent to 1 mg dexamethasone
Study: NCT02939456

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Double Inversion Recovery Magnetic Resonance Imaging (DIR-MRI) and Dynamic Contrast Enhanced Magnetic Imaging (DCE-MRI)
Study: NCT03444831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Buspirone 5mg used QID a day after meal plus 20mg omeprazole before breakfast.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Buspirone placebo QID after meal plus 20mg omeprazole before breakfast.
Study: NCT02051257

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01978548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 10 mg
Description: JNJ-54861911 10 mg will be administered as two 5 mg oral tablets once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 50 mg
Description: JNJ-54861911 50 mg will be administered as two 25 mg oral tablets once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as 2 oral tablets once daily.
Study: NCT03490734

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Black Cherry and Orange Flavored Beverage with added sugar
Description: 10 oz daily for three weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Strawberry Kiwi &Lemonade Flavored Beverage with added sugar
Description: 10 oz daily for three weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Black Cherry and Orange Flavored Beverage no added sugar
Description: 10 oz daily for three weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Strawberry Kiwi & Lemonade Flavored Beverage no added sugar
Description: 10 oz daily for three weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Three mL administered per associated logo presentation only during MRI procedure.
Study: NCT02473276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sterile normal saline
Description: sterile normal saline, given either via an epidural or intrathecal catheter

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sterile normal saline
Description: sterile normal saline, given either via an epidural or intrathecal catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sterile normal saline
Description: sterile normal saline, given either via an epidural or intrathecal catheter
Study: NCT03490734

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Three mL administered per associated logo presentation only during MRI procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Three mL administered per associated logo presentation only during MRI procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Three mL administered per associated logo presentation only during MRI procedure.
Study: NCT02715635

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Typhoid vaccine
Description: The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Typhoid vaccine
Description: The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
Study: NCT02473276

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sterile normal saline
Description: sterile normal saline, given either via an epidural or intrathecal catheter
Study: NCT01233388

Intervention type: OTHER
Intervention: Text message surveillance
Description: Text message surveillance for vaccine adverse events
Study: NCT01472744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance Group
Description: Participants will be instructed and learn various forms of dance (i.e. English country, folk, ballroom) and will be led by trained dance instructors and exercise specialists. Participants will for one-hour sessions and meet three times per week for six months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength, Stretching, Stability
Description: Exercises focusing on strength, flexibility and balance will be performed at one-hour sessions held three times per week for six months. Classes are led by trained exercise specialists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. They will be provided with heart rate monitors and pedometers for accurate record keeping. They will meet three times per week for one hour for six months. Warm up and cool down stretches will be a part of each walking session and sessions will be monitored and led by trained exercise specialists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. They will be provided with heart rate monitors and pedometers for accurate record keeping. They will meet three times per week for one hour for six months. Warm up and cool down stretches will be a part of each walking session and sessions will be monitored and led by trained exercise specialists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking + Nutrition
Description: Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. They will be provided with heart rate monitors and pedometers for accurate record keeping. They will meet three times per week for one hour for six months. Warm up and cool down stretches will be a part of each walking session and sessions will be monitored and led by trained exercise specialists. These participants will also be provided with a daily nutritionally balanced liquid, milk-based supplement formula.
Study: NCT02445573

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EA
Description: When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In EA group, participants were needled at bilateral BL33 at an angle of 30 to 45 degree inward and downward, and at bilateral BL35 slightly toward upside and outside, to a depth of 50 to 60 mm using acupuncture needles of size 0.30×75 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral BL33 and BL35 (using real electrodes) respectively, with a continuous wave of 50 Hz and a current intensity of 1-5 milliampere (mA) for 30 min. Participants were treated with EA 3 sessions a week on alternate days for 6 successive weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham EA
Description: When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In sham EA group, participants were needled at sham BL33 and sham BL35, which were about 20 mm lateral to BL33 and BL35, respectively, with blunt needle tips piercing adhesive pads and not piercing the surface of the skin, using placebo needles of size 0.30×25 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral sham BL33 and sham BL35 (using sham electrodes) respectively. The parameters of sham EA apparatus and the treatment course were the same as in the EA group.
Study: NCT04928729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pursed Lip Breathing
Description: PLB with frequency of three times daily for First 3 days of week for a duration of 5-10 mins is perform.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pursed Lip Breathing +DB
Description: PLB+DB with frequency of three times daily for Last three days of week for a duration of 10-15 mins is perform.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative care
Description: Participants will be having different dose as per tolerance 5 times daily.
Study: NCT02471638

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PQ Bypass System for Femoropopliteal Bypass
Description: To access, deliver guidewires and implant stent grafts for a percutaneous fem-pop bypass.
Study: NCT02760810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Marketed Contact Lens
Description: Narafilcon A
Study: NCT02855944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy will be administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Tablets of rucaparib, at a dose of 600 mg, will be taken orally twice a day
Study: NCT02715635

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Concentrate beetroot Juice
Description: 140 ml containing \~8 mmol of inorganic nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Concentrate beetroot Juice (Placebo)
Description: 140 ml which is nitrate-depleted
Study: NCT00538993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage based counseling
Study: NCT03470363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane Volatile Liquid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine / SUFentanil
Study: NCT02846012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSCM2
Study: NCT01329913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6325
Description: Two 100 mg capsules, orally, once per day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6325
Description: Two 100 mg capsules, orally, once per day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-6325
Description: Two 100 mg capsules, orally, once per day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-6325
Description: Two 100 mg capsules, orally, once per day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6325
Description: Four 100 mg capsules, orally, once per day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6325
Description: Four 100 mg capsules, orally, once per day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-6325
Description: Four 100 mg capsules, orally, once per day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-6325
Description: Four 100 mg capsules, orally, once per day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6325
Description: Eight 100 mg capsules, orally, once per day for 7 days
Study: NCT02499380

Intervention type: DEVICE
Intervention: PneumRx Coil System
Study: NCT03336307

Intervention type: OTHER
Intervention: Rehabilitation program
Description: all patients received a rehabilitation program planned according to the European Physiotherapy guideline for Parkinson's disease and focus on:~* endurance, strength, flexibility and balance with functional practice for all H/Y stage~* endurance also for H/Y stage 1,~* motor learning principles and cue functional for H/Y stage 2-3~* external cues and self-instruction strategies and attention H/Y for stage 2-3 The rehabilitative program comprised 60-minute sessions a day (3d/wk).